Pharma Tech

BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

Jul 28, 2026, 9:30 AM

Read Full Article → BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

Translate article text

Choose a language and wait for the translated text.

BioMarin Pharmaceutical and n-Lorem Foundation have entered a collaboration and licence agreement to develop an investigational ASO therapy for ReNU syndrome.